{"schema_version":"secwatch.filing_event.v1","accession":"0001770787-22-000004","form_type":"8-K","ticker":"TXG","cik":"0001770787","company_name":"10x Genomics, Inc.","filed_at":"2022-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.140517+00:00","generated_at":"2026-06-27T07:36:17.965974+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"10x Genomics reports FY 2021 revenue $490.5M (+64% YoY); guides FY 2022 revenue $600-630M","bullets":["Revenue $490.5M FY 2021, up 64% from $298.8M in FY 2020; Q4 revenue $143.5M, up 28% from $112.2M.","Gross margin 85% FY 2021 vs 80% in 2020, due to lower royalties and manufacturing efficiencies.","Operating loss $52.3M FY 2021 vs $534.1M in 2020, which included $447.5M acquisition-related R&D charges.","Net loss $58.2M FY 2021 vs $542.7M in 2020; cash and equivalents $587.4M as of Dec 31, 2021.","FY 2022 revenue guidance $600-630M, representing 22-28% growth over FY 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001770787-22-000004","json":"https://secwatch.observer/filing/0001770787-22-000004.json","markdown":"https://secwatch.observer/filing/0001770787-22-000004.md","text":"https://secwatch.observer/filing/0001770787-22-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770787/000177078722000004/0001770787-22-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770787/000177078722000004/txg-20220216.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T07:36:17.965974+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}